Internal Medicine, Medical Oncology · New York, NY
NPI
1861659500
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
160 E 53rd St, 9th Floor
New York, NY, 10022
Phone (212) 610-0590
Groups this clinician bills Medicare through
Medicare paid, 2024
$95K
1,034 services
Medicare patients, 2024
262
Average age 74
Drug cost, 2024
$6.6M
1,249 prescriptions
Company payments, 2025
$39K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jamie E Chaft was code 99214 (office e&m - established), 407 times for 176 patients. In total Jamie E Chaft billed 1,034 services in 13 codes, and Medicare paid $95K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-04-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 407 | 176 | $81.33 | $33K |
| 99215 Office E&M - Established | Office | 335 | 158 | $117.21 | $39K |
| 99213 Office E&M - Established | Office | 195 | 94 | $55.87 | $11K |
| 99205 Office E&M - New | Office | 44 | 44 | $151.82 | $6,680 |
| 99233 Hospital E&M - Subsequent | Facility | 28 | 19 | $103.21 | $2,890 |
By year: 2022 $75K for 728 services; 2023 $115K for 1,222 services; 2024 $95K for 1,034 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jamie E Chaft prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 298 prescriptions and refills. In total Jamie E Chaft wrote 1,249 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 298 | 298 | 40 | $4.9M |
| Dexamethasone Generic | 109 | 112 | 56 | $1,238 |
| Prochlorperazine Maleate Generic | 68 | 68 | 47 | $508 |
| Prednisone Generic | 57 | 61 | 28 | $236 |
| Levothyroxine Sodium Generic | 53 | 66 | 15 | $184 |
| Pantoprazole Sodium Generic | 40 | 60 | 19 | $475 |
| Lorbrena Lorlatinib | 37 | 37 | Under 11 | $710K |
| Xarelto Rivaroxaban | 36 | 42 | Under 11 | $23K |
| Folic Acid Generic | 35 | 47 | 13 | $276 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 28 | 31 | 13 | $114 |
| Eliquis Apixaban | 26 | 44 | Under 11 | $24K |
| Ondansetron Hcl Generic | 25 | 29 | 19 | $128 |
| Omeprazole Generic | 25 | 35 | 12 | $79.21 |
| Erlotinib Hcl Generic | 25 | 25 | Under 11 | $2,115 |
| Alecensa Alectinib Hcl | 22 | 22 | Under 11 | $240K |
Brand drugs: 489 claims; generic drugs: 760 claims; opioid claims: 18.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jamie E Chaft $39K ($39K in general payments such as food, travel and fees and $557 for research) from 15 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $14K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 6 | $14K |
| Eli Lilly and Company LLY | 1 | $9,900 |
| AstraZeneca UK Limited AZN | 4 | $5,375 |
| EMD Serono, Inc. MRK.DE | 1 | $3,800 |
| Merck Sharp & Dohme LLC MRK | 11 | $3,090 |
| Nuvation Bio Inc. NUVB | 1 | $2,100 |
| F. Hoffmann-La Roche AG ROG.SW | 2 | $557 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $169 |
| Genentech USA, Inc. ROG.SW | 1 | $151 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.